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Abstract 
Genomics-driven growth in the number of enzymes of unknown function has created a need for better 
strategies to characterize them. Since enzyme inhibitors have traditionally served this purpose, we 
present here an efficient systems-based inhibitor design strategy, enabled by bioinformatic and NMR 
structural developments. First, we parse the oxidoreductase gene family into structural subfamilies 
termed pharmacofamilies, which share pharmacophore features in their cofactor binding sites. Then 
we identify a ligand for this site and use NMR-based binding site mapping (NMR SOLVE) to determine 
where to extend a combinatorial library, such that diversity elements are directed into the adjacent 
substrate site. The cofactor mimic is reused in the library in a manner that parallels the reuse of 
cofactor domains in the oxidoreductase gene family. A library designed in this manner yielded specific 
inhibitors for multiple oxidoreductases. 
  
Introduction 
Proteomes are inherently modular since most domains in proteins belong to superfamilies common to 
many organisms,1, 2, 3 and proteins are generally thought to be created by gene duplication and 
shuffling of a limited repertoire of domains.1, 2 For instance, oxidoreductases frequently use the same 
Rossmann fold domain to bind the NAD(P)(H) cofactor but use an additional unique domain for the 
substrate that defines the function for a given enzyme. The presence of the conserved cofactor binding 
site, coupled with the modular nature of this gene family, has led us to develop a highly parallel 
approach to inhibitor design. In this chemical proteomic strategy, focused chemical libraries are 
tailored to subfamilies of large gene families to produce nM inhibitors for multiple members of the 
subfamily. The parallel production of inhibitors across a gene family such as the oxidoreductases will 
have applications in chemogenomic and functional genomic efforts to define protein functions, as well 
as in drug design. The latter is a significant point considering the large number of new proteins and 
drug targets being identified as a result of functional genomics efforts.4 Inhibitors for various members 
of the oxidoreductase gene family could be used to generate chemical knockouts as a probe of protein 
function in vivo (chemogenomics) or of protein-ligand interactions in vitro (chemical proteomics). Such 
molecules, if designed for optimal ADMET (adsorption, distribution. metabolism, excretion, and 
toxicology) properties could even serve as early-stage leads in a parallel drug discovery program. 
Such a systems-based approach to inhibitor design requires a solid understanding of the common 
binding sites in a gene family. Since cofactor conformation is a reflection of the common binding site 
shape, we had previously performed cluster analysis5 on cofactors extracted from 288 oxidoreductase 
crystal structures. In that study,6 oxidoreductases clustered into subfamilies termed pharmacofamilies 
that were related by cofactor geometry, protein sequence, and protein fold (SCOP classification). These 
structural proteomic studies are being extended and used herein to enable a parallel/gene family-
based approach to the design of bi-ligand inhibitors. NMR methods are used to design bi-ligand 
libraries off of a privileged scaffold that occupies the cofactor site, which is conserved within the 
pharmacofamily. The strategy is finally validated by the identification of potent bi-ligand inhibitors for 
multiple members of this pharmacofamily. 
Results and Discussion 
Structural Proteomic Analysis of Oxidoreductases: pharmacofamilies 
The conserved cofactor geometry for oxidoreductases is apparent in Figure 1, where cofactors have 
been overlaid for members of the largest pharmacofamily, the two-domain Rossmann fold proteins. 
There are two subfamilies that differ only by a 180° rotation around the glycosidic bond, with 
pharmacofamily 1 having the nicotinamide ring anti and pharmacofamily 2 having the nicotinamide 
ring syn[6]. Especially relevant for the current studies is that this conservation of cofactor geometry is 
paralleled by a conservation of binding site features that describe the pharmacophore for this family. 
The conserved heteroatoms that define the hydrogen bond donors and acceptors that comprise this 
pharmacophore are shown in Figure 1C. The major oxidoreductase pharmacofamilies are summarized 
in Figure 1D, and initial studies reported herein focus on enzymes in pharmacofamilies 1 and 2. The 
only differences between pharmacofamilies 1 and 2 is the placement of groups around the 
carboxamide substituent on the nicotinamide ring. Noteworthy is the tendency of the carbonyl of the 
carboxamides to point in the same direction, affecting the relative placement of hydrogen bond donors 
(to the carboxamide C = O) and acceptors (from the carboxamide −NH2) within a pharmacofamily. 
Figure 1. Pharmacofamilies 1 and 2 
(A) Structure of the NADH cofactor bound by the oxidoreductases. 
(B) Overlays of a unique subset of NAD(P)(H) geometries obtained from 288 crystal structures of 
oxidoreductases, yielding pharmacofamilies related by the geometry of bound cofactor. The largest 
families are shown here, corresponding to the two-domain Rossmann fold enzymes in pharmacofamilies 
1 (anti) and 2 (syn). 
(C) Corresponding pharmacophores for pharmacofamilies 1 and 2, with all protein heteroatoms 
indicated that are within hydrogen bonding distance of atoms in the cofactor in the binding site. Regions 
occupied by Thr104 and Thr80 in E. coli DHPR (dihydrodipicolinate reductase) are indicated for 
reference. 
(D) Summary of the major pharmacofamilies that were previously derived based on parsing the 
oxidoreductases according to geometry of bound cofactor.6 Geometry around the C-N glycosidic bond 
connecting nicotinamide and ribose rings is indicated. 
 
The binding site for the nicotinamide ring of the cofactor is always close to the substrate site since the 
nicotinamide ring is involved in a hydride transfer reaction with the substrate. Although the binding 
site for the cofactor is conserved within a pharmacofamily, the adjacent substrate site is quite variable. 
This variability is reflected in the diversity of substrates acted on by oxidoreductases. We analyzed 460 
oxidoreductase substrates7 in terms of properties of interest in the drug design process8(Figure 2). 
Although most oxidoreductase substrates are in the 100–180 Da range and of modest hydrophobicity, 
there are a number with molecular weights in the 550 and 850 Da range, and some that are quite 
hydrophobic, with AlogP (Ghose and Crippen water/octanol partitioning9) values in excess of five. 
 
Figure 2. Range of Calculated and Predicted Physicochemical Properties of Oxidoreductase Substrates as Well as 
Specificity Ligands (SLs) Used in the Bi-Ligand Library 
Key chemical properties of these diversity elements are compared with those for 460 known 
oxidoreductase substrates.7 Calculated properties are: (A) molecular weight; (B) AlogP, a measure of 
hydrophobicity; (C) number of hydrogen bond acceptors; and (D) number of hydrogen bond donors. 
Modular Inhibitor Design Strategy to Parallel a Modular Gene Family 
 
Proteins that are evolutionarily related and have conserved pharmacophore features in a binding site 
would be expected to have similar ligand binding preferences. As such, our systems-based approach to 
the design of bi-ligand inhibitors of oxidoreductases begins within a pharmacofamily, initially chosen to 
be the two-domain Rossmann fold family (Figure 1) because it is the largest and most well-
characterized pharmacofamily. Oxidoreductases, viewed in a systems-based manner, are comprised of 
two adjacent binding sites: the NAD(P)H cofactor (common ligand) and substrate (specificity ligand) 
binding sites, exemplified in Figure 3 with the enzyme dihydrodipicolinate reductase (DHPR). The 
inhibitor design strategy used herein parallels the modular design of the oxidoreductase gene family11 
and produces inhibitors across a pharmacofamily, since it starts by identifying a small molecule that 
binds in the common ligand site (a common ligand mimic or CLM) for that class of proteins. Diversity 
elements are then directed from the CLM into the adjacent specificity site in the construction of a bi-
ligand library. 
  
 Figure 3. Comparison of Binding Modes for Computationally Docked Cofactor Analog and the NADH Cofactor 
(A) Computationally docked structure of the propylamide derivative of CLM-1 (white) in the E. coli DHPR 
binding site, overlaid on the NADH structure (yellow) and adjacent to the 2,6-pyridine dicarboxylate 
(PDC) substrate analog (green). Docking was done with the docking algorithm contained within the MOE 
software package (Chemical Computing Group), with the MMFF94 forcefield and with the 1arz 
coordinates for DHPR.10 Binding site threonine residues are identified in brown, with methyl groups 
rendered as balls. Proximity of methyl groups on the CLM's propylamide group, Thr104, and Thr170 to 
the PDC ligand is indicated with dashed lines. 
(B) A solvent-accessible surface map color coded by partial charge (red, negative; blue, positive), with 
the region surrounding the negatively charged catechol oxygen shown expanded. In the expansion, red 
is the surface exposed para-hydroxyl group of CLM-1, and the four surrounding blue regions represent 
guanido groups of arginines 81, 16, 39, and 19 that approach within 5.5, 5.7, 7.0, and 9.0 Å, respectively. 
 
Identification and Characterization of CLMs 
We selected CLM candidates computationally by matching the pharmacophore properties of the 
nicotinamide mononucleotide portion of NADH bound to DHPR,10 an oxidoreductase in 
pharmacofamily 1, and an enzyme essential for cell wall synthesis in Mycobacterium tuberculosis,12 
This ligand-based search employed the icosahedral matching algorithm13 contained within the 
THREEDOM software package (Interprobe, Inc.) to identify potential inhibitors, which were then 
purchased and tested against DHPR as well as other dehydrogenases in this pharmacofamily. The most 
drug-like and crossreactive of these were resynthesized and retested. Crossreactivity is a desired 
property, since a CLM is effectively a privileged scaffold that is going to provide baseline affinity across 
a pharmacofamily, with further increases in affinity later achieved for specific targets by directing bi-
ligand libraries into the variable substrate pocket. One of the inhibitors identified in this screening 
process was modified to produce a more potent and soluble analog by replacing a phenyl ring with an 
acetic acid group, resulting in CLM-1 (Table 1; Figure 4). The modeled structure of a propylamide 
derivative of CLM-1 is shown docked into the binding site of DHPR and overlaid on NADH (Figure 3A). 
The docked structure binds in a mode that differs from that originally predicted based on direct 
comparisons to cofactor, which may be a reflection of an inherent symmetry in the NADH molecule 
that has a nicotinamide ring on one end and an adenine ring on the other. Indeed, another low-energy 
docked structure had the propylamide group in the adenine site, but the orientation shown here with 
the propylamide group proximal to the substrate site is most consistent with the NMR SOLVE data 
described below. The electrostatic surface shown in Figure 3B indicates that the catechol ring is 
somewhat solvent exposed and surrounded by positive charge density from adjacent arginines. 
Table 1. Affinity and Specificity of CLM and Bi-Ligand Molecules for Oxidoreductases in 
pharmacofamilies 1 and 2 
Structurea LDHb DHPRb DOXPRb 
 
 
 
 
55 μM 26 μM >50 μM 
 
42 nMc >50 μM 10 μM 
 
12 μM >25 μM 202 nMc 
 
620 nM 100 nMc 7.9 μM 
a While the SL of the first bi-ligand was condensed with the carboxylic acid of the linker in Figure 5C, the 
other 2 SLs were condensed with the acid of the shorter linker on CLM-1.15 
b Numbers are Kis values except for DOXPR, which has an IC50, which should approximate a Kis. LDH 
(lactate dehydrogenase) and DHPR are in pharmacofamily 1, while DOXPR (1-deoxy-D-xylulose-5-
phosphate reductoisomerase) is in pharmacofamily 2.6 
c Most potent inhibition value amongst the three enzymes is indicated in bold. 
  
Figure 4. Computationally Selected Cofactor Analogs and Steady-State Characterization as a Cofactor Analog 
(A) A representative set of 11 computationally selected and tested cofactor mimics, with the top 
structure being the only one that showed significant inhibitory activity. 
(B) Steady-state inhibition profile for CLM-1, which is a modified form of the top inhibitor in (A). Profile 
is with inhibitor versus NADPH. Profile represents the fit to the equation for a competitive inhibitor with 
a squared dependence on inhibitor concentration. The fit gave a Kis value of 26 ± 2 μM. Curves for 
alcohol dehydrogenase (Kis = 101 μM), lactate dehydrogenase (Kis = 55 μM), and DOXPR (Kis > 50 μM) fit 
best to a model for competitive inhibition. 
 
All computationally selected CLM candidates were commercially available and tested for binding 
potency through steady-state kinetic inhibition studies with DHPR, with a representative set of 
compounds shown in Figure 4A. CLMs that bind at the NAD(P)(H) site were identified based on 
inhibition profiles. For example, CLM-1 is a competitive inhibitor versus NADPH and, therefore, likely 
binds in the cofactor binding site. Interestingly, the inhibition pattern showed a squared dependence 
on concentration, suggesting that some synergy might exist between sequential binding events to the 
DHPR tetramer. The fit was best to a competitive model, with no apparent intercept effect in double 
reciprocal plots (Figure 4B). 
Determining the Expansion Point for the Bi-Ligand Library with NMR SOLVE 
We then experimentally determined the CLM's orientation and relative position in the cofactor binding 
site by the NMR SOLVE method.11, 14 The NMR SOLVE method begins by mapping a binding site relative 
to a reference ligand, such as cofactor, and then characterizing the binding mode of a novel ligand, 
such as a CLM, relative to the reference ligand. Key information obtained with NMR SOLVE is where a 
linker should be placed such that chemical diversity elements can be attached and directed into an 
adjacent specificity pocket. In order to avoid problems with spectral overlap in 2D NMR experiments, 
studies were performed on deuterated and sparsely labeled protein, with the 1H-13C label present only 
in the methyl groups of the 8-Met, 16-Ile, and 14-Thr residues in DHPR. Previously, we had mapped the 
DHPR binding site with NADH as a reference ligand11(Figure 5A). Now, we used these assignments for 
key binding site residues to orient a CLM candidate relative to where the reference cofactor had 
bound. Although the acid version of the best CLM (CLM-1, Table 1 and Figure 4) showed interaction 
primarily between its catechol ring and the distal Thr80 (data not shown), the propylamide derivative 
in Figure 5B showed a clear nuclear Overhauser effect (NOE) between the terminal methyl of the CLM 
and the 2,6-pyridinedicarboxylate (PDC) substrate antagonist, which itself showed an NOE to the 
Thr104 interface residue. PDC also showed an NOE to a residue assigned to the substrate site (Thr170). 
PDC is a stable analog of the reactive dihydrodipicolinate substrate and is used here to help mimic the 
ternary complex that would normally form in the steady-state catalytic cycle. Based on the NOE to 
PDC, the end of the propylamide functionality therefore appears to be the appropriate place for 
attaching a specificity ligand. We then used a carboxylic acid functionality here as a bi-ligand library 
expansion point. To verify that this functionality also resides in the substrate site, we compared 2D 
HMQC spectra (Figure 5C) for each version of this CLM, with and without the terminal carboxylic acid 
(red and blue crosspeaks). This chemical perturbation of the ligand caused the largest changes in the 
crosspeak for Thr170, a residue known to reside in the substrate site, and to a residue at the interface 
of the cofactor and substrate sites (Thr104). These data largely confirmed the docked structure in 
Figure 3A, since the terminal methyl of the propylamide is that part of the CLM that is closest to PDC 
(within 5 Å). It should be noted that the NMR SOLVE experiments would have suggested the same 
library expansion point in the absence of any protein structural information, since crosspeaks for 
threonine residues were assigned based on proximity to reference ligands (NADH and PDC). That is, it 
was never necessary to assign Thr104 to a specific residue number, as it would have been adequate to 
view it only as the crosspeak for the residue at the interface of the NADH and PDC binding sites. 
Structural data were included here only to illustrate the method. The NMR data not only suggested the 
bi-ligand library expansion point, but it also confirmed that PDC binding mode was not significantly 
altered in the CLM:PDC:DHPR ternary complex (compared to the NADH:PDC:DHPR ternary complex), 
since PDC showed the same pattern of NOEs to threonine methyl protons in both complexes. Finally, 
the selective perturbation of active site methyl proton chemical shifts in the complex with CLM and the 
complex with the bi-ligand (see below) allow us to rule out any nonspecific mechanism for inhibition 
that could have produced competitive inhibition profiles, at least for these inhibitors. 
 
Figure 5. NMR SOLVE Data for DHPR 
(A) The binding site is mapped relative to the NADH cofactor, identifying NMR probe atoms.14 
(B) NOESY data for a CLM-1 analog, which places the methyl terminus of the propylamide functionality 
closest to the SL site. 
(C) Chemical alteration of the end of this alkyl chain in creating CLM-2 produces changes to crosspeaks 
for atoms in the SL site in the overlay of HMQC spectra for complexes of DHPR with both versions of the 
CLM (red and blue). 
(D) HMQC spectra of DHPR in the absence (red) and presence (blue) of the bi-ligand inhibitor. 
Validation of the NMR-Selected Library Expansion Point 
Based on these NMR data, CLM-1 was linked to PDC, the specificity ligand analog. The corresponding 
bi-ligand compound had a Kis of 100 nM, which represents a 250-fold increase in affinity over the 
starting CLM (Table 1). The common and specificity sites were both occupied, based on NMR chemical 
shift mapping studies showing perturbations of residues in both binding sites (Figure 5D). Although the 
squared effect on inhibition complicated steady-state analysis, analogous bi-ligands were made with 
the same specificity ligand but with variants of the CLM that gave less pronounced cooperativity 
effects. Steady-state kinetic profiles for two of these bi-ligand molecules are shown in Figure 6, 
showing a best fit to a competitive inhibition model versus both the NADPH and dihydrodipicolinate 
substrates, as expected for a bi-ligand inhibitor. 
 
Figure 6. Steady-State Inhibition Profiles for Bi-Ligand Molecules with CLMs that Are Variants of CLM-1 
Bi-ligand structures are shown to the left of their respective inhibition profiles. Curves fit best to 
equations where inhibition was competitive versus both cofactor (NADPH) and substrate. Enzyme was E. 
coli DHPR. The first bi-ligand was varied (0, 400, 750, 1100, 1500 nM) versus NADPH and gave a Kis of 
370 ± 90 nM (A), and versus dihydrodipicolinate (DHP) gave a Kis of 170 ± 50 nM (B). The second bi-
ligand was varied (0, 500, 1000, 1500, 2000 nM) versus NADPH and gave a Kis of 500 ± 100 nM (C), and 
versus dihydrodipicolinate gave a Kis of 530 ± 140 nM (D). 
Building the Focused Bi-Ligand Library 
The last step of this systems-based bi-ligand design process involves the addition of diversity elements 
to the CLM such that they are directed into the substrate (specificity ligand [SL]) site in the manner 
suggested by NMR SOLVE. Although the geometric relationship of the CLM and SL sites is conserved in 
oxidoreductases, the actual size and electrostatic properties of the SL binding site will vary in a way 
that parallels the diversity of substrates used by oxidoreductases, as discussed above. The diversity 
elements attached to the conserved CLM scaffold were matched to the properties of substrates used 
throughout the oxidoreductase gene family in that they roughly paralleled the distribution of the 
chemical properties surveyed in Figure 2. 
We selected 300 diversity elements (commercially available) and chemically joined them to the CLM-
linker construct. The resulting bi-ligand library was then screened against three Rossmann-fold 
enzymes in pharmacofamilies 1 and 2: DHPR, lactate dehydrogenase (LDH), and 1-deoxy-D-xylulose-5-
phosphate reductoisomerase (DOXPR). The starting CLM bound only weakly to the three enzymes, with 
Kis values in the 25–100 μM range (Table 1). However, after adding the diversity elements in the 
position selected with NMR SOLVE, steady-state enzyme kinetic screening identified a specific bi-ligand 
inhibitor of LDH with a Kis of 42 nM and a best fit to a model for competitive inhibition. This represents 
an increase in affinity over the starting CLM of a thousand-fold, with most of the increased affinity 
directed toward specificity interactions, since the bi-ligand binds two to three orders of magnitude 
stronger to LDH than to DHPR or DOXPR. We also identified a bi-ligand inhibitor that bound with an 
IC50 of 202 nM to DOXPR, also with selectivity. Based on these data, we propose that a bi-ligand 
collection of sufficient size and diversity, built with an appropriately chosen CLM and well placed 
linkers, will produce nM inhibitors for most members of a pharmacofamily. 
Thermodynamic Foundation for Gene Family Focused Bi-Ligand Libraries 
Fragment-based assembly strategies are a very efficient means of designing inhibitors.16, 17, 18 The 
systems-based bi-ligand design process described herein makes fragment assembly more likely to 
produce inhibitors for multiple, related proteins, since the CLM fragment provides a baseline of affinity 
across a pharmacofamily (ΔGCLM). Furthermore, since the mere joining of two molecular fragments has 
been proposed to provide as much as 45 entropy units, corresponding to an increase in affinity of 108-
fold19, 20 associated with the “chelate effect,” the combined effect of adding a CLM to an SL could be as 
large as 108/KCLM fold. This could only occur for those SLs binding in the specificity pocket adjacent to 
the CLM, thus ensuring that linkage with the CLM provides specificity for a given oxidoreductase. 
Although the full magnitude of the chelate effect is still being investigated by researchers, it is in any 
case quite large and reports of enhancements in affinity or rates approaching 108-fold have been 
reported.21 In practice, only a tiny fraction of this affinity increase will ever be fully realized because 
linkers might be flexible, produce nonoptimal placement of the CLM and SL ligands, or have repulsive 
interactions with a binding site. Still, this combinatorial strategy for fragment linkage is an efficient way 
of focusing a library, since even imperfect linkage can produce large affinity boosts for multiple 
enzymes within a pharmacofamily. 
Significance 
Genomes have now been sequenced for numerous organisms, and expectations are that this 
information will provide a better understanding of biology, as well as yield new and better 
therapeutics. This cannot be realized until more efficient strategies are developed to characterize 
proteins, and tools are created to translate this knowledge into inhibitors as mechanistic probes and 
drugs. To this end, we had previously reported a structural proteomic analysis of oxidoreductases, 
which comprise 2%–4% of most proteomes.6 Herein, we presented a systems-based strategy for 
designing inhibitors of oxidoreductases. This strategy parallels nature's modular approach for designing 
the oxidoreductase gene family itself. Chemical libraries designed in this manner could be used as a 
source of chemogenomic probes for defining functions of members of the oxidoreductase gene family, 
as well as a source of drug leads for the many new targets being identified in functional genomics 
efforts. 
Experimental Procedures 
Computational Search for CLMs 
Computational methods were used to identify CLM candidates to be tested as cofactor mimics. 
Coordinates of the nicotinamide mononucleotide (NMN) portion of the NADH cofactor were extracted 
from the structure of cofactor in complex with DHPR (pdb code: 1arz). These coordinates were used to 
search against databases of commercially available compounds (such as from ASINEX [Moscow, 
Russia]), which contained molecules with precalculated three-dimensional structures. The search was 
quite fast since it involved only matching the shape of the NMN portion of the cofactor to the 
precalculated structures in the small molecule database through an icosahedral matching algorithm.13, 
22 Still, an ellipsoid shape prefilter was used as a first screen to identify molecules that were roughly 
the shape of NMN to prescreen and eliminate obviously poor matches. To address heteroatom 
composition and hydrogen bonding capabilities at an approximate level, hybrid shape-matching scores 
were used. Shapes were compared both as a function of all atoms and as a function of heteratoms 
only, with scores weighted equally in the hybrid score. After prefiltering the circa 40,000 molecules, 
shape-matching scores were calculated with the THREEDOM software package by comparing full 
structures or only the heteratoms. These two sets of scores were combined to create an average 
“hybrid” score through Perl scripts developed in-house. Generally around 5% of the computationally 
selected compounds were found to inhibit one of the three dehydrogenases tested. Although searches 
against the full-length NADH cofactor produced a somewhat higher hit rate (up to 10% versus lactate 
dehydrogenase), these compounds were not used due to their higher molecular weight and 
unsuitability as drug leads. 
Computational Docking of the Propylamide Derivative of CLM-1 
The propylamide derivative of CLM-1 was docked into the crystal structure of the DHPR/NADH/2,6-PDC 
ternary complex after removing the cofactor. First, the ligand was minimized by AM1 (Gaussian98) 
with a net charge of –1, localized on the para-hydroxy group of the catechol ring. Docking was then 
performed with the MOE software package (Chemical Computing Group) and the MMFF94 forcefield, 
with ligand flexible and protein kept rigid. Protein was also energy minimized (MMFF94) before 
docking, and then 25 docking runs were performed with random starting orientations. Optimization 
was with simulated annealing, with an initial temperature of 1000 K and six cycles per run. Docking 
calculations included protein atoms within a 62 Å × 62 Å × 62 Å box surrounding the site previously 
occupied by cofactor. The choice to dock into the cofactor site was based on the observation of 
competitive inhibition patterns (with the more soluble CLM-1) versus cofactor in the steady-state 
enzyme kinetic studies described below. One of the two lowest energy structures is shown in Figure 
3A, with the NADH structure overlaid back in its original orientation so that the relative binding mode 
of CLM-1 derivative and “reference” cofactor can be compared. Although the lowest energy structure 
had the propylamide group extending into the adenine site, only the orientation shown in Figure 3A 
was consistent with the NMR SOLVE data described below. A solvent-accessible surface map color 
coded by partial charge is shown in Figure 3B, with the region surrounding the negative (red) catechol 
ring shown in the expansion. The four surrounding blue regions represent guanido groups of arginines 
81, 16, 39, and 19 that approach within 5.5, 5.7, 7.0, and 9.0 Å, respectively, of the charged oxygen of 
the catechol ring. 
Synthesis of Bi-Ligand Library 
The 3,4-dihydroxyphenylmethylene-rhodanine CLM (CLM-1) was synthesized by heating a solution of 
13.6 g 3,4-dihydroxybenzaldehyde, and 19.3 g rhodanine acetic acid at 95°C in 200 ml acetic acid for 6 
hr. After cooling the solution, the precipitate was collected and washed with acetic acid (2 × 5 mL) to 
give 20 g of product CLM-1. The CLM-1 acid (or amine; 1.5 eq) and PS-carbodiimide resin (2 eq) were 
reacted in THF (10 mL/g) for 1 hr. The desired amine (or acid) to be conjugated to the CLM-1 was then 
added (1 eq) and reacted overnight. Product was extracted twice with THF and solvent evaporated to 
give desired product. 
Protein Production 
The E. coli DHPR protein was expressed with a pET21a vector (Novagen) and purified as described 
previously.14 Briefly, DHPR was uniformly enriched in 2H and 15N and contained 1H/15N/13C-labeled 
threonine, 1H/13C(δ-methyl)-labeled isoleucine, and 1H/13C(ϵ-methyl)-labeled methionine, and was 
produced through a modified version of supplemented M9 minimal media. Purification was on a Q 
Sepharose anion exchange column (Amersham). The DOXPR gene was cloned from E. coli genomic DNA 
by PCR utilizing the following primers: 5′-GCCACTGCATATGAAGCAACTCACCATTCTGG and 3′-
GCCACTGGGATCCTCAGCTTGCGAGACGCATC. DOXPR was expressed and purified as reported.14, 23 
Steady-State Inhibition Studies 
All reactions were monitored spectrophotometrically at 340 nm by using initial rates from the first 5% 
of reaction. Absorbance changes at 340 nm are from production or consumption of NAD(P)H cofactor. 
LDH reaction mixtures contained 100 mM Hepes buffer (pH 7.4), 2.5 mM pyruvate, 10 μM NADH, and 5 
ng/mL lactate dehydrogenase. DOXPR reaction mixtures contained 100 mM Hepes buffer (pH 7.4), 1.2 
mM DOXP, 8 μM NADPH, 1 mM MnCl2, and 10 μg/mL DOXPR. DHPR reactions were as described 
previously,24 with either NADH or NADPH cofactor. In all cases when screening bi-ligands, nonvaried 
substrate concentrations were kept close to their Km values. Data were fitted to appropriate equations 
for competitive, noncompetitive, and uncompetitive inhibition through nonlinear least-squares 
fitting.25 Mechanism of inhibition was established through analysis of the overall sigma value for the fit, 
as well as the magnitude of standard deviations for inhibition constants (Kii, Kis). The inhibition pattern 
for CLM-1 (Table 1) showed a squared dependence on inhibitor concentration (Figure 4B), still fitting 
best to a competitive model:  
 
where v is the initial velocity, I is inhibitor concentration, Kis is the slope inhibition constant, A is 
cofactor (NADH) concentration, Vmax is the maximum velocity, and Km is the Michaelis constant. 
NMR Spectroscopy 
NMR experiments were performed on a Bruker DRX700 spectrometer equipped with a triple resonance 
probe and triple axis gradient coil. Tetrameric DHPR concentration was ∼75 μM (300 μM monomer) in 
25 mM Tris-D11 buffer (pH 7.8) at a temperature of 303 K, with a sample volume of 150 μl in Shigemi 
tubes, as described previously.14 Most NMR experiments were performed in the presence of the PDC 
substrate analog along with either NADH or CLM, in order to mimic the active ternary complex that is 
produced in the steady-state catalytic cycle. PDC was not used for studies of bi-ligands or for the 
inhibitors being compared in Figure 5C. PDC is a fairly potent substrate analog, with a Kis value of 26 
μM versus the dihydrodipicolinate substrate.24 Selective WURST adiabatic decoupling26 of the γ from 
the β 13C of Thr was used in NMR experiments to decrease overlap of the 14 Thr residues. Typical 2D 
[13C,1H] HMQC spectra were recorded in 30 min. Typical 2D [1H,1H] NOESY spectra were acquired with 
256 × 2048 complex points and with mixing times between 50 and 500 ms. 13C decoupling during 
acquisition was with a GARP composite decoupling sequence,27 while 13Cγ decoupling during the 
evolution period was with a 180° refocusing pulse. Ambiguities due to proton overlap among Thr and 
Met methyl proton chemical shifts were removed by recording a 3D [13C,1H] resolved [1H,1H] NOESY 
experiment.28 NOEs were later verified as not being due to spin diffusion through the QUIET-NOESY 
experiment.29, 30 
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